▶ 調査レポート

パーキンソン病治療薬の世界市場:作用メカニズム別(ドーパミン作用薬、抗コリン作用薬、MAO-B阻害剤、アセチルコリンエステラーゼ阻害剤、NMDAアンタゴニスト、COMT阻害剤、選択的セロトニンインバースアゴニスト(SSIA))、地域別分析

• 英文タイトル:Global Parkinson’s Disease Drugs Market - Segmented by Mechanism of Action and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。パーキンソン病治療薬の世界市場:作用メカニズム別(ドーパミン作用薬、抗コリン作用薬、MAO-B阻害剤、アセチルコリンエステラーゼ阻害剤、NMDAアンタゴニスト、COMT阻害剤、選択的セロトニンインバースアゴニスト(SSIA))、地域別分析 / Global Parkinson’s Disease Drugs Market - Segmented by Mechanism of Action and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08438資料のイメージです。• レポートコード:B-MOR-08438
• 出版社/出版日:Mordor Intelligence / 2018年5月1日
• レポート形態:英文、PDF、112ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User(1名様用)¥442,000 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥468,000 (USD4,500)▷ お問い合わせ
  Corporate User¥910,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、パーキンソン病治療薬の世界市場について調べ、パーキンソン病治療薬の世界規模、市場動向、市場環境、作用メカニズム別(ドーパミン作用薬、抗コリン作用薬、MAO-B阻害剤、アセチルコリンエステラーゼ阻害剤、NMDAアンタゴニスト、COMT阻害剤、選択的セロトニンインバースアゴニスト(SSIA))分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・パーキンソン病治療薬の世界市場インサイト
・パーキンソン病治療薬の世界市場環境
・パーキンソン病治療薬の世界市場動向
・パーキンソン病治療薬の世界市場規模
・パーキンソン病治療薬の世界市場規模:作用メカニズム別(ドーパミン作用薬、抗コリン作用薬、MAO-B阻害剤、アセチルコリンエステラーゼ阻害剤、NMDAアンタゴニスト、COMT阻害剤、選択的セロトニンインバースアゴニスト(SSIA))
・パーキンソン病治療薬の世界市場:地域別市場規模・分析
・パーキンソン病治療薬の北米市場規模・予測
・パーキンソン病治療薬のアメリカ市場規模・予測
・パーキンソン病治療薬のヨーロッパ市場規模・予測
・パーキンソン病治療薬のアジア市場規模・予測
・パーキンソン病治療薬の日本市場規模・予測
・パーキンソン病治療薬の中国市場規模・予測
・パーキンソン病治療薬のインド市場規模・予測
・パーキンソン病治療薬の韓国市場規模・予測
・関連企業情報・競争状況

The Parkinson’s disease drugs market is expected to witness a CAGR of 6.2% during the forecast period, 2018-2023. The global Parkinson’s disease drug market has witnessed a remarkable growth in the recent years, due to a large patient pool and increased diagnosis rates.

Recent Drug Approvals

Researchers are working to develop new and improved therapies for people with Parkinson’s disease (PD). There have been many drugs that have been approved to treat Parkinson disease. In January 2015, the US FDA approved an extended release formulation of levodopa/carbidopa. Recently in January 2018, Adamas Pharmaceuticals Inc. has launched Gocovri (amantadine extended-release capsules) for the treatment of dyskinesia in people with Parkinson’s, who are taking levodopa. This is the first drug indicated specifically for dyskinesia, which is developed with the long-term usage of levodopa. These newly-approved drugs, with different formulations, are addressing different unmet needs and are expected to drive the Parkinson disease drug market.
The other factors, which are also driving the market, include increasing demand due to the higher prevalence of the disease, new entrants expected to balance generic intrusion, and increasing use of the MAO-B inhibitor.

Generic Competition to Key Therapies

In the coming years, many of the Parkinson’s disease branded drugs are expected to lose their patent. For instance, these patent expirations include Azilect (rasagiline mesylate), Stalevo (levodopa, carbidopa, entacapone) and Comtan (entacapone). After expiration, the already-approved generic alternatives to these drugs can be marketed at a low price, resulting in competition. According to Novartis, annual report of 2016, the Parkinson’s disease drug business for the United States and Europe were majorly being affected by the availability of generic drugs, such as Exelon (rivastigmine tartrate), in the market. The release of the premium product is expected to face intense competition against the generic alternatives present in the market, which will restrain the global market.
The other restraining factor is the high cost of treatment and absence of revolutionary products in the near future.

Europe Holds the Largest Share of the Market

Geographically, Europe is expected to hold the largest share of the market in 2017 followed by North America, Asia-Pacific and the rest of the world. Europe is also expected to command the Parkinson’s disease treatment market. A large share of the European market in this segment can be attributed to the growing aging population, presence of key players, and increasing healthcare expenditure in the region. Asia is expected to grow at the highest CAGR, during the forecast period.

Key Developments in the Market

• January 2018: Pfizer, the world’s third-largest drug maker, announced that it is ending research to discover new medications for Alzheimer’s and Parkinson’s diseases, due to the high cost involved.
• January 2018: Adamas Pharmaceuticals Inc. launched Gocovri (amantadine extended-release capsules) for the treatment of dyskinesia.

Major Players: MERCK & CO. INC., IMPAX LABORATORIES INC., ABBVIE INC., MYLAN NV, BOEHRINGER INGELHEIM, GLAXOSMITHKLINE PLC., SOMERSET PHARMACEUTICALS INC., TEVA PHARMACEUTICALS, PFIZER, NOVARTIS AG, JOHNSON & JOHNSON (JANSSEN), AND ALLERGAN PLC amongst others.

Reasons to Purchase the Report

• Current and future market outlook for Parkinson’s disease drugs in the developed and emerging markets
• Analyze various perspectives on the market, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth, during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the market estimate sheet (in Excel)

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Demand Owing to Higher Prevalence of the Disease
6.1.2 Recent Drug Approvals
6.1.3 New Entrants Expected to Balance Generic Intrusion
6.1.4 Increasing Use of the MAO-B Inhibitor
6.2 Market Restraints
6.2.1 Generic Competition to Key Therapies
6.2.2 High Cost of Treatment
6.2.3 Absence of Revolutionary Products in Near Future
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Mechanism of Action
7.1.1 Dopamine Agonists
7.1.1.1 Carbidopa/levodopa (Sinemet, Sinemet CR, Rytary, Duopa)
7.1.1.2 Apomorphine (Apokyn)
7.1.1.3 Pramipexole (Mirapex, Mirapex ER)
7.1.1.4 Ropinirole (Requip and Requip XL)
7.1.1.5 Amantadine
7.1.1.6 Rotigotine (Neupro)
7.1.2 Anticholinergic
7.1.2.1 Trihexyphenidyl
7.1.2.2 Benztropine mesylate (Cogentin)
7.1.3 MAO-B inhibitors
7.1.3.1 Selegiline (Eldepryl)
7.1.3.2 Rasagiline (Azilect)
7.1.4 Acetylcholinesterase Inhibitors, Central
7.1.4.1 Donepezil (Aricept)
7.1.4.2 Rivastigmine (Exelon)
7.1.4.3 Galantamine (Razadyne, Razadyne ER)
7.1.5 NMDA Antagonists
7.1.5.1 Memantine (Namenda, Namenda XR)
7.1.6 COMT Inhibitors
7.1.6.1 Tolcapone (Tasmar)
7.1.6.2 Entacapone (Comtan)
7.1.6.3 Carbidopa, Levodopa, and Entacapone (Stalevo)
7.1.7 Selective Serotonin Inverse Agonists (SSIA)
7.1.7.1 Pimavanserin (Nuplazid)
7.2 By Geography
7.2.1 North America
7.2.1.1 United States
7.2.1.2 Canada
7.2.1.3 Mexico
7.2.2 Europe
7.2.2.1 France
7.2.2.2 Germany
7.2.2.3 United Kingdom
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 China
7.2.3.2 Japan
7.2.3.3 India
7.2.3.4 Australia & New Zealand
7.2.3.5 South Korea
7.2.3.6 Rest of Asia-Pacific
7.2.4 Middle East & Africa
7.2.4.1 GCC
7.2.4.2 South Africa
7.2.4.3 Rest of the Middle East & Africa
7.2.5 South America
7.2.5.1 Brazil
7.2.5.2 Argentina
7.2.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Merck & Co. Inc.
9.2 Impax Laboratories Inc.
9.3 AbbVie Inc.
9.4 Mylan NV
9.5 Boehringer Ingelheim
9.6 GlaxoSmithKline PLC
9.7 Somerset Pharmaceuticals Inc.
9.8 Teva Pharmaceuticals
9.9 Pfizer
9.10 Novartis AG
9.11 Johnson & Johnson (Janssen)
9.12 Allergan Plc
9.13 Takeda Pharmaceutical Company
9.14 List Not Exhaustive
10. Future of the Market